Earnings Call Summary | Owens & Minor(OMI.US) Q2 2024 Earnings Conference
Earnings Call Summary | Owens & Minor(OMI.US) Q2 2024 Earnings Conference
The following is a summary of the Owens & Minor, Inc. (OMI) Q2 2024 Earnings Call Transcript:
以下是Owens & Minor, Inc. (OMI) Q2 2024業績會議要點摘要:
Financial Performance:
金融業績:
Owens & Minor reported a Q2 revenue of $2.7 billion, up 4% compared to the prior year.
Gross profit for the quarter was $544 million, reflecting a margin expansion of 11 basis points from the previous year.
GAAP operating income for the quarter increased by 87% year-over-year to $20.3 million, and adjusted operating income was up 23% at $76.3 million.
Owens & Minor報告Q2營業收入爲27億美元,比去年同期增長4%。
本季度毛利潤爲5440萬美元,較去年同期擴大11個點子的利潤率。
本季度按照GAAP計算的運營收入同比增長87%,達到2030萬美元,調整後的運營收入同比增長23%,達到7630萬美元。
Business Progress:
業務進展:
Announced the acquisition of Rotech Healthcare Holdings, aligning with strategic plans to expand the Patient Direct business to a revenue target of $5 billion by 2028.
Reported advancements in operational efficiencies, reducing manufacturing, transportation, and distribution costs with improvements in both major business segments making strides towards their strategic goals.
宣佈收購Rotech Healthcare Holdings,以擴大Patient Direct 業務,目標是在2028年達到50億美元的收入。
報告運營效率的改善,減少了製造、運輸和分銷成本,兩個重要的業務部門在實現戰略目標方面都取得了進展。
Opportunities:
機會:
Demographic trends indicating a growth in chronic conditions provide a solid base for the expansion of the Patient Direct segment.
The acquisition of Rotech Healthcare Holdings is expected to enhance service delivery and reach in home-based healthcare.
人口統計趨勢表明,慢性病病例的增長爲Patient Direct業務的擴張提供了堅實的基礎。
收購Rotech Healthcare Holdings預計將增強在家庭保健領域的服務交付和覆蓋範圍。
Risks:
風險:
Faced challenges with net new customer onboarding, which extended backlogs into Q2, potentially impacting future service timelines and customer satisfaction.
面臨新客戶入門的挑戰,在Q2中出現積壓,可能影響未來的服務時間表和客戶滿意度。
More details: Owens & Minor IR
更多詳情:Owens & Minor IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。